PPA
PTGX icon

Parametric Portfolio Associates’s Protagonist Therapeutics PTGX Stock Holding History

Parametric Portfolio Associates’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$942K Buy
39,771
+17,120
+76% +$482K ﹤0.01% 2808
2021
Q4 		$775K Buy
22,651
+2,217
+11% +$70.1K ﹤0.01% 2888
2021
Q3 		$362K Sell
20,434
-50,966
-71% -$2.17M ﹤0.01% 3226
2021
Q2 		$3.2M Buy
71,400
+31,201
+78% +$1.03M ﹤0.01% 2154
2021
Q1 		$1.04M Sell
40,199
-8,303
-17% -$210K ﹤0.01% 3146
2020
Q4 		$978K Buy
+48,502
New +$1.04M ﹤0.01% 3067
2020
Q2 		– Sell
-17,931
Closed -$127K – 3984
2020
Q1 		$127K Sell
17,931
-268
-1% -$2.01K ﹤0.01% 3676
2019
Q4 		$128K Buy
18,199
+644
+4% +$6.39K ﹤0.01% 3826
2019
Q3 		$211K Buy
17,555
+322
+2% +$4.06K ﹤0.01% 3688
2019
Q2 		$209K Buy
17,233
+106
+0.6% +$1.17K ﹤0.01% 3730
2019
Q1 		$215K Sell
17,127
-1,553
-8% -$13.7K ﹤0.01% 3696
2018
Q4 		$126K Sell
18,680
-702
-4% -$5.57K ﹤0.01% 3755
2018
Q3 		$199K Sell
19,382
-3,775
-16% -$32.5K ﹤0.01% 3766
2018
Q2 		$156K Buy
+23,157
New +$178K ﹤0.01% 3747

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Parametric Portfolio Associates's PTGX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Protagonist Therapeutics (PTGX) stake by 76% in Q1 2022, buying an estimated $482K and bringing the position to 39,771 shares worth $942K. The position accounts for ﹤0.01% of the portfolio, ranked #2808.

Parametric Portfolio Associates first reported a position in PTGX in Q2 2018 and has held it in 14 quarters since. The position peaked at $3.2M in Q2 2021. 141 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

  • Parametric Portfolio Associates held 39,771 shares of Protagonist Therapeutics worth $942K as of Q1 2022.
  • Parametric Portfolio Associates bought 17,120 Protagonist Therapeutics shares in Q1 2022, an estimated $482K.
  • Protagonist Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2808 holding.
  • Parametric Portfolio Associates first reported a position in Protagonist Therapeutics in Q2 2018 and has held it in 14 quarters since.
  • Parametric Portfolio Associates's Protagonist Therapeutics position peaked at $3.2M in Q2 2021.
  • 141 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.